ISARIC has been committed to provide a wide breadth of COVID-19 clinical research resources since the beginning of the outbreak. These resources are fully adaptable and completely free to use
The tools below aim to cover a range of tiers, suitable for different needs. Whether you are aiming to just collect standardised data, contribute with your data to ISARIC’s ever growing clinical database or start your own study on COVID-19, ISARIC’s COVID-19 presents fully adaptable data collection solutions for different needs.
Professor Bin Cao with a COVID-19 patient (Photo credit: Professor Bin Cao, China-Japan Friendship Hospital, China)
For the collection of standardised clinical data to improve patient care and inform the public health response.
Optional CRF Modules
These modules have been developed in collaboration with WHO and international experts to be used in addition to the Core or RAPID COVID-19 CRFs when applicable, depending on resources and research need.
We currently have two modules available: COVID-19 Rapid Critical Care and COVID-19 CRF Module for Pregnant Women
Multisystem inflammatory syndrome (MIS-C) in children and adolescents
This CRF has been developed in collaboration with WHO’s working group.
This Case Report Form (CRF) has been developed to use as a standalone CRF for children and adolescents presenting with syndrome of suspected Multisystem Inflammatory Syndrome (MIS-C).
COVID-19 Data Management & Hosting
The ISARIC Clinical Data Platform is a secure electronic data capture system and repository that standardises and secures global data on COVID-19.
Ownership and control of all data entered on this system are retained by those who enter the data.
COVID-19 Evidence & Data Reports
ISARIC Partners are invited to lead and participate in collaborative analyses of the ISARIC Global Data Platform.
Staff from sites and networks contributing to the ISARIC database, defined as ‘ISARIC Partners’, can request to initiate an analysis.
Clinical Characterisation Protocol (CCP)
ISARIC/WHO protocol for standardised clinical data collection (+/- sampling)
The CCP It is a standardised protocol that enables data and biological samples to be collected rapidly in a globally-harmonised manner. It may be used for the rapid, coordinated clinical investigation of confirmed cases of COVID-19. It is fully adaptable and ISARIC encourages its global use. Data collection forms:
Acute phase (Core, Rapid, optional modules) and Tier 1 follow up survey
COVID-19 Long term protocol & survey
Standardised clinical data collection
Study protocol and a patient survey for serial follow up of patients with confirmed COVID-19, to standardise data collection to facilitate timely, robust analysis to assess frequency and risk factors for long term health and psychosocial consequences of COVID-19.
COVID-19 CCP Global Toolkit
ISARIC has developed developed a range of free downloadable materials to provide guidance on the Global Clinical Characterisation protocol
Visit the toolkit for an overview of the main steps for implementation of the CCP. There are also two case studies available to help guide the implementation process.
COVID-19 Rapid Evidence Reviews Group (CORRE)
A collaborative effort to provide high quality rapid evidence synthesis for use in COVID-19 research.
Reports produced by the COVID-19 Rapid Evidence Reviews Group seek to provide an answer to a list of relevant research questions.
The final purpose is to accelerate our collective understanding of COVID-19 to help improve patient care and inform public health policy.
Associated clinical studies in COVID-19
Clinical data collection with the aims of building a research or study
ISARIC has many member networks, who are involved in patient-based research, to generate an evidence-based response to COVID 19, and has also provided support to several clinical trials, some of which are mentioned here.
Visit this section to find ISARIC’s articles, studies and more.
In January 2020, ISARIC launched an international initiative for standardised COVID-19 clinical data collection. Over the past nine months, there has been extensive global participation, resulting in one of the world’s largest collections of comprehensive clinical data for COVID-19.
ISARIC, based at Oxford University, in collaboration with Dr Janet Scott, of the MRC-University of Glasgow’s Centre for Virus Research, has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19.
The international, multi-site study is launched by ISARIC to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study.